Evidence map›Paper›PMID 28300073›Full record

ArticleScientific reports2017

Actin-binding protein coronin 1A controls osteoclastic bone resorption by regulating lysosomal secretion of cathepsin K.

Saori Ohmae, Naruto Noma, Masayasu Toyomoto, Masahiro Shinohara, Masatoshi Takeiri, Hiroaki Fuji, Kenji Takemoto, Keiko Iwaisako, Tomoko Fujita, Norihiko Takeda and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Saori OhmaeInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Naruto NomaInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Masayasu ToyomotoDepartment of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Masahiro ShinoharaDepartment of Systems BioMedicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Masatoshi TakeiriInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Hiroaki FujiInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Kenji TakemotoInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Keiko IwaisakoDepartment of Target Therapy Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Tomoko FujitaInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Norihiko TakedaPRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama, Japan.
Makoto KawataniChemical Biology Research Group, RIKEN CSRS, Wako, Saitama, Japan.
Mineyoshi AoyamaDepartment of Pathobiology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Masatoshi HagiwaraDepartment of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Yasushi IshihamaDepartment of Molecular and Cellular BioAnalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.
Masataka AsagiriInnovation Center for Immunoregulation and Therapeutics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
Kyoto University · JPNagoya City University · JPRIKEN · JPThe University of Tokyo · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoclasts degrade bone matrix proteins via the secretion of lysosomal enzymes. However, the precise mechanisms by which lysosomal components are transported and fused to the bone-apposed plasma membrane, termed ruffled border membrane, remain elusive. Here, we identified coronin 1A as a negative regulator of exocytotic release of cathepsin K, one of the most important bone-degrading enzymes in osteoclasts. The modulation of coronin 1A expression did not alter osteoclast differentiation and extracellular acidification, but strongly affected the secretion of cathepsin K and osteoclast bone-resorption activity, suggesting the coronin 1A-mediated regulation of lysosomal trafficking and protease exocytosis. Further analyses suggested that coronin 1A prevented the lipidation-mediated sorting of the autophagy-related protein LC3 to the ruffled border and attenuated lysosome-plasma membrane fusion. In this process, the interactions between coronin 1A and actin were crucial. Collectively, our findings indicate that coronin 1A is a pivotal component that regulates lysosomal fusion and the secretion pathway in osteoclast-lineage cells and may provide a novel therapeutic target for bone diseases.

Indexed as

ActinsAnimalsBone ResorptionCathepsin KCell DifferentiationGene ExpressionGene Expression RegulationLysosomesMiceMicrofilament ProteinsOsteoclastsProtein BindingProtein TransportRANK LigandActinsCathepsin Kcoronin proteinsMicrofilament ProteinsRANK Ligand

Identifiers

PMID28300073
PMCPMC5353622
OpenAlexW2597240806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.